Magnetic particle targeting for diagnosis and therapy of lung cancers
- PMID: 32920079
- PMCID: PMC7484624
- DOI: 10.1016/j.jconrel.2020.09.017
Magnetic particle targeting for diagnosis and therapy of lung cancers
Abstract
Over the past decade, the growing interest in targeted lung cancer therapy has guided researchers toward the cutting edge of controlled drug delivery, particularly magnetic particle targeting. Targeting of tissues by magnetic particles has tackled several limitations of traditional drug delivery methods for both cancer detection (e.g., using magnetic resonance imaging) and therapy. Delivery of magnetic particles offers the key advantage of high efficiency in the local deposition of drugs in the target tissue with the least harmful effect on other healthy tissues. This review first overviews clinical aspects of lung morphology and pathogenesis as well as clinical features of lung cancer. It is followed by reviewing the advances in using magnetic particles for diagnosis and therapy of lung cancers: (i) a combination of magnetic particle targeting with MRI imaging for diagnosis and screening of lung cancers, (ii) magnetic drug targeting (MDT) through either intravenous injection and pulmonary delivery for lung cancer therapy, and (iii) computational simulations that models new and effective approaches for magnetic particle drug delivery to the lung, all supporting improved lung cancer treatment. The review further discusses future opportunities to improve the clinical performance of MDT for diagnosis and treatment of lung cancer and highlights clinical therapy application of the MDT as a new horizon to cure with minimal side effects a wide variety of lung diseases and possibly other acute respiratory syndromes (COVID-19, MERS, and SARS).
Keywords: Acute respiratory syndromes; Intravenous injection; Lung cancer; Magnetic drug targeting; Magnetic resonance imaging (MRI); Pulmonary delivery.
Copyright © 2020 Elsevier B.V. All rights reserved.
Figures



Similar articles
-
Numerical simulation of magnetic drug targeting for lung cancer therapy using a bulk superconducting magnet.Drug Deliv. 2025 Dec;32(1):2490836. doi: 10.1080/10717544.2025.2490836. Epub 2025 Apr 29. Drug Deliv. 2025. PMID: 40299317 Free PMC article.
-
Magnetic aerosol drug targeting in lung cancer therapy using permanent magnet.Drug Deliv. 2019 Dec;26(1):120-128. doi: 10.1080/10717544.2018.1561765. Drug Deliv. 2019. PMID: 30798633 Free PMC article.
-
Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.Curr Pharm Des. 2017;23(3):481-494. doi: 10.2174/1381612822666161027113654. Curr Pharm Des. 2017. PMID: 28292243 Review.
-
Delivery of magnetic micro/nanoparticles and magnetic-based drug/cargo into arterial flow for targeted therapy.Drug Deliv. 2018 Nov;25(1):1963-1973. doi: 10.1080/10717544.2018.1497106. Drug Deliv. 2018. PMID: 30799655 Free PMC article.
-
The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.Nanomedicine (Lond). 2010 Nov;5(9):1415-33. doi: 10.2217/nnm.10.113. Nanomedicine (Lond). 2010. PMID: 21128723 Review.
Cited by
-
Numerical simulation of magnetic drug targeting for lung cancer therapy using a bulk superconducting magnet.Drug Deliv. 2025 Dec;32(1):2490836. doi: 10.1080/10717544.2025.2490836. Epub 2025 Apr 29. Drug Deliv. 2025. PMID: 40299317 Free PMC article.
-
Magnetic field-induced synergistic therapy of cancer using magnetoplasmonic nanoplatform.Mater Today Bio. 2024 Dec 7;30:101393. doi: 10.1016/j.mtbio.2024.101393. eCollection 2025 Feb. Mater Today Bio. 2024. PMID: 39759844 Free PMC article.
-
Development of ZHPV16E7- granzyme B immunoaffitoxin: dual mechanisms targeting hpv16-positive cervical cancer through epithelial-mesenchymal transition inhibition and cell death.Front Immunol. 2025 Jul 21;16:1616715. doi: 10.3389/fimmu.2025.1616715. eCollection 2025. Front Immunol. 2025. PMID: 40761801 Free PMC article.
-
Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.J Funct Biomater. 2023 Sep 9;14(9):466. doi: 10.3390/jfb14090466. J Funct Biomater. 2023. PMID: 37754880 Free PMC article. Review.
-
PEGylated green halloysite/spinel ferrite nanocomposites for pH sensitive delivery of dexamethasone: A potential pulmonary drug delivery treatment option for COVID-19.Appl Clay Sci. 2022 Jan;216:106333. doi: 10.1016/j.clay.2021.106333. Epub 2021 Nov 9. Appl Clay Sci. 2022. PMID: 34776567 Free PMC article.
References
-
- van Rijt S.H., Bein T., Meiners S.J.E.R.J. Medical nanoparticles for next generation drug delivery to the lungs. Eur. Respir. J. 2014;44:765–774. erj02128-02013. - PubMed
-
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. - PubMed
-
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. - PubMed
-
- Gridelli C., Rossi A., Carbone D.P., Guarize J., Karachaliou N., Mok T., Petrella F., Spaggiari L., Rosell R. Non-small-cell lung cancer. Nat. Rev. Dis. Primers. 2015;1:15009. - PubMed
-
- Kalemkerian G.P. Seminars in respiratory and critical care medicine. Thieme Medical Publishers; 2016. Small cell lung cancer; pp. 783–796. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous